A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.
The firm is developing the immunotherapy IMNN-001 for treating ovarian cancer and assessing its efficacy in patients with homologous recombination deficiency.